Campbell David Alan 4
4 · Janux Therapeutics, Inc. · Filed Jan 8, 2025
Insider Transaction Report
Form 4
Campbell David Alan
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2025-01-07$60.00/sh−5,000$300,004→ 293,054 total
Footnotes (2)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024.
- [F2]The weighted average sale price for the transaction reported was $60.0008 and the range of prices were between $60.00 and $60.02. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.